Home » Stocks » Zogenix

Zogenix, Inc. (ZGNX)

Stock Price: $20.73 USD -0.56 (-2.63%)
Updated Oct 26, 2020 4:00 PM EDT - Market closed
After-hours: $20.98 +0.25 (1.21%) Oct 26, 7:24 PM

Stock Price Chart

Key Info

Market Cap 1.15B
Revenue (ttm) 4.86M
Net Income (ttm) -425.66M
Shares Out 55.45M
EPS (ttm) -8.91
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 26, 2020
Last Price $20.73
Previous Close $21.29
Change ($) -0.56
Change (%) -2.63%
Day's Open 21.10
Day's Range 20.50 - 21.19
Day's Volume 880,126
52-Week Range 16.65 - 57.22

More Stats

Market Cap 1.15B
Enterprise Value 771.84M
Earnings Date (est) Nov 10, 2020
Ex-Dividend Date n/a
Shares Outstanding 55.45M
Float 54.14M
EPS (basic) -9.45
EPS (diluted) -8.91
FCF / Share -2.79
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 6.69M
Short Ratio 3.76
Short % of Float 12.35%
Beta 1.59
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 236.51
PB Ratio 2.91
Revenue 4.86M
Operating Income -461.55M
Net Income -425.66M
Free Cash Flow -154.55M
Net Cash 377.59M
Net Cash / Share 6.81
Gross Margin -2,304.34%
Operating Margin -9,496.83%
Profit Margin -8,758.50%
FCF Margin -3,179.98%
ROA -22.32%
ROE -97.76%
ROIC -241.10%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (12)

Buy 9
Overweight 0
Hold 3
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(123.64% upside)
Current: $20.73
Target: 46.36
*Average 12-month price target from 11 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth---65.96%6.14%-6.1%-12.31%-25.52%17.96%60.29%-
Gross Profit3.65--0.916.684.839.3411.7724.8318.2810.60
Operating Income-424-140-95.84-70.89-49.73-38.62-44.94-47.43-76.42-70.16
Net Income-420-124-127-69.7126.148.59-80.86-47.39-83.90-73.56
Shares Outstanding43.0837.8827.3024.7921.4517.8313.5710.075.340.52
Earnings Per Share-9.74-3.27-4.65-2.811.220.48-5.96-4.72-15.68-141.04
EPS Growth----154.17%-----
Operating Cash Flow-112-112-75.87-72.88-64.60-80.82-44.92-52.20-80.47-71.95
Capital Expenditures-9.49-1.02-0.08-0.10-0.31-0.12-0.81-0.29-0.62-3.44
Free Cash Flow-121-113-75.95-72.98-64.91-80.94-45.73-52.50-81.09-75.39
Cash & Equivalents25151429491.5516550.7172.0241.2356.5349.17
Total Debt12.07--22.0922.2223.1528.8028.4856.9126.90
Net Cash / Debt23951429469.4614327.5543.2212.75-0.3822.27
Book Value24552330212118355.2818.4314.479.3128.73
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Zogenix, Inc.
Country United States
Employees 141
CEO Stephen James Farr

Stock Information

Ticker Symbol ZGNX
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: ZGNX
IPO Date November 23, 2010


Zogenix, a pharmaceutical company, develops and commercializes transformative therapies to enhance the lives of patients and their families living with rare diseases in the United States. The company's lead product candidate is the Fintepla, a low-dose fenfluramine, which is in Phase III clinical trials for the treatment of seizures associated with Dravet syndrome and Lennox-Gastaut syndrome (LGS); and which is in Phase II clinical trials for the treatment of other rare epileptic syndromes and diseases. It also developing MT1621, an investigational deoxynucleoside substrate enhancement therapy for the treatment of inherited mitochondrial DNA depletion disorder thymidine kinase 2 deficiency (TK2d). The company was formerly known as SJ2 Therapeutics, Inc. and changed its name to Zogenix, Inc. in August 2006. Zogenix, Inc. was founded in 2006 and is headquartered in Emeryville, California.